Royce & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-5,340
| Closed | -$235K | – | 993 |
|
|
2021
Q2 | $235K | Sell |
5,340
-592
| -10% | -$26.1K | ﹤0.01% | 980 |
|
|
2021
Q1 | $293K | Sell |
5,932
-4,748
| -44% | -$235K | ﹤0.01% | 984 |
|
|
2020
Q4 | $450K | Buy |
10,680
+170
| +2% | +$7.16K | ﹤0.01% | 903 |
|
|
2020
Q3 | $481K | Buy |
10,510
+32
| +0.3% | +$1.47K | 0.01% | 867 |
|
|
2020
Q2 | $526K | Buy |
10,478
+136
| +1% | +$6.83K | 0.01% | 853 |
|
|
2020
Q1 | $532K | Buy |
10,342
+3,062
| +42% | +$158K | 0.01% | 821 |
|
|
2019
Q4 | $450K | Buy |
7,280
+3,597
| +98% | +$222K | ﹤0.01% | 902 |
|
|
2019
Q3 | $221K | Buy |
3,683
+3,403
| +1,215% | +$204K | ﹤0.01% | 974 |
|
|
2019
Q2 | $24K | Buy |
280
+5
| +2% | +$429 | ﹤0.01% | 1102 |
|
|
2019
Q1 | $26K | Sell |
275
-13
| -5% | -$1.23K | ﹤0.01% | 1104 |
|
|
2018
Q4 | $20K | Buy |
288
+25
| +10% | +$1.74K | ﹤0.01% | 1106 |
|
|
2018
Q3 | $22K | Buy |
263
+141
| +116% | +$11.8K | ﹤0.01% | 1147 |
|
|
2018
Q2 | $14K | Buy |
122
+17
| +16% | +$1.95K | ﹤0.01% | 1181 |
|
|
2018
Q1 | $8K | Sell |
105
-83
| -44% | -$6.32K | ﹤0.01% | 1207 |
|
|
2017
Q4 | $11K | Buy |
+188
| New | +$11K | ﹤0.01% | 1166 |
|